

Approval and implementation dates for specific health plans may vary. Please consult the applicable health plan for more details.

## Clinical Appropriateness Guidelines

# Advanced Imaging

# Appropriate Use Criteria: Imaging of the Chest

### Proprietary

© 2024 Carelon Medical Benefits Management, Inc. All rights reserved.

# Table of Contents

Table of Contents .....	2
Description and Application of the Guidelines .....	3
General Clinical Guideline .....	5
Clinical Appropriateness Framework .....	5
Simultaneous Ordering of Multiple Diagnostic or Therapeutic Interventions.....	5
Repeat Diagnostic Intervention .....	5
Repeat Therapeutic Intervention .....	6
Imaging of the Chest.....	7
General Information/Overview.....	7
Clinical Indications.....	9
Congenital and Developmental Conditions.....	9
Infectious and Inflammatory Conditions .....	9
Trauma.....	10
Tumor or Neoplasm .....	11
Parenchymal Lung Disease – not otherwise specified.....	14
Pleural Conditions.....	16
Chest Wall and Diaphragmatic Conditions.....	17
Perioperative or periprocedural evaluation, not otherwise specified .....	18
Signs and Symptoms.....	18
Abnormal Test Findings .....	21
References.....	22
Codes.....	24
History .....	24

## Description and Application of the Guidelines

The Carelon Clinical Appropriateness Guidelines (hereinafter “the Carelon Clinical Appropriateness Guidelines” or the “Guidelines”) are designed to assist providers in making the most appropriate treatment decision for a specific clinical condition for an individual. The Guidelines establish objective and evidence-based criteria for medical necessity determinations, where possible, that can be used in support of the following:

- To establish criteria for when services are medically necessary
- To assist the practitioner as an educational tool
- To encourage standardization of medical practice patterns
- To curtail the performance of inappropriate and/or duplicate services
- To address patient safety concerns
- To enhance the quality of health care
- To promote the most efficient and cost-effective use of services

The Carelon guideline development process complies with applicable accreditation and legal standards, including the requirement that the Guidelines be developed with involvement from appropriate providers with current clinical expertise relevant to the Guidelines under review and be based on the most up-to-date clinical principles and best practices. Resources reviewed include widely used treatment guidelines, randomized controlled trials or prospective cohort studies, and large systematic reviews or meta-analyses. Carelon reviews all of its Guidelines at least annually.

Carelon makes its Guidelines publicly available on its website. Copies of the Guidelines are also available upon oral or written request. Additional details, such as summaries of evidence, a list of the sources of evidence, and an explanation of the rationale that supports the adoption of the Guidelines, are included in each guideline document.

Although the Guidelines are publicly available, Carelon considers the Guidelines to be important, proprietary information of Carelon, which cannot be sold, assigned, leased, licensed, reproduced or distributed without the written consent of Carelon.

Carelon applies objective and evidence-based criteria, and takes individual circumstances and the local delivery system into account when determining the medical appropriateness of health care services. The Carelon Guidelines are just guidelines for the provision of specialty health services. These criteria are designed to guide both providers and reviewers to the most appropriate services based on a patient’s unique circumstances. In all cases, clinical judgment consistent with the standards of good medical practice should be used when applying the Guidelines. Guideline determinations are made based on the information provided at the time of the request. It is expected that medical necessity decisions may change as new information is provided or based on unique aspects of the patient’s condition. The treating clinician has final authority and responsibility for treatment decisions regarding the care of the patient and for justifying and demonstrating the existence of medical necessity for the requested service. The Guidelines are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment.

The Guidelines do not address coverage, benefit or other plan specific issues. Applicable federal and state coverage mandates take precedence over these clinical guidelines, and in the case of reviews for Medicare Advantage Plans, the Guidelines are only applied where there are not fully established CMS criteria. If requested by a health plan, Carelon will review requests based on health plan medical policy/guidelines in lieu of the Carelon Guidelines. Pharmaceuticals, radiotracers, or medical devices used in any of the diagnostic or therapeutic interventions listed in the Guidelines must be FDA approved or conditionally approved for the intended use. However, use of an FDA approved or conditionally approved product does not constitute medical necessity or guarantee reimbursement by the respective health plan.

The Guidelines may also be used by the health plan or by Carelon for purposes of provider education, or to review the medical necessity of services by any provider who has been notified of the need for medical necessity review, due to billing practices or claims that are not consistent with other providers in terms of frequency or some other manner.

# General Clinical Guideline

## Clinical Appropriateness Framework

---

Critical to any finding of clinical appropriateness under the guidelines for a specific diagnostic or therapeutic intervention are the following elements:

- Prior to any intervention, it is essential that the clinician confirm the diagnosis or establish its pretest likelihood based on a complete evaluation of the patient. This includes a history and physical examination and, where applicable, a review of relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention.
- The anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to services that may result (net benefit).
- Widely used treatment guidelines and/or current clinical literature and/or standards of medical practice should support that the recommended intervention offers the greatest net benefit among competing alternatives.
- There exists a reasonable likelihood that the intervention will change management and/or lead to an improved outcome for the patient.

Providers may be required to submit clinical documentation in support of a request for services. Such documentation must a) accurately reflect the clinical situation at the time of the requested service, and b) sufficiently document the ordering provider's clinical intent.

If these elements are not established with respect to a given request, the determination of appropriateness will most likely require a peer-to-peer conversation to understand the individual and unique facts that would justify a finding of clinical appropriateness. During the peer-to-peer conversation, factors such as patient acuity and setting of service may also be taken into account to the extent permitted by law.

## Simultaneous Ordering of Multiple Diagnostic or Therapeutic Interventions

---

Requests for multiple diagnostic or therapeutic interventions at the same time will often require a peer-to-peer conversation to understand the individual circumstances that support the medical necessity of performing all interventions simultaneously. This is based on the fact that appropriateness of additional intervention is often dependent on the outcome of the initial intervention.

Additionally, either of the following may apply:

- Current literature and/or standards of medical practice support that one of the requested diagnostic or therapeutic interventions is more appropriate in the clinical situation presented; or
- One of the diagnostic or therapeutic interventions requested is more likely to improve patient outcomes based on current literature and/or standards of medical practice.

## Repeat Diagnostic Intervention

---

In general, repeated testing of the same anatomic location for the same indication should be limited to evaluation following an intervention, or when there is a change in clinical status such that additional testing is required to determine next steps in management. At times, it may be necessary to repeat a test using different techniques or protocols to clarify a finding or result of the original study.

Repeated testing for the same indication using the same or similar technology may be subject to additional review or require peer-to-peer conversation in the following scenarios:

- Repeated diagnostic testing at the same facility due to technical issues

- Repeated diagnostic testing requested at a different facility due to provider preference or quality concerns
- Repeated diagnostic testing of the same anatomic area based on persistent symptoms with no clinical change, treatment, or intervention since the previous study
- Repeated diagnostic testing of the same anatomic area by different providers for the same member over a short period of time

## **Repeat Therapeutic Intervention**

---

In general, repeated therapeutic intervention in the same anatomic area is considered appropriate when the prior intervention proved effective or beneficial and the expected duration of relief has lapsed. A repeat intervention requested prior to the expected duration of relief is not appropriate unless it can be confirmed that the prior intervention was never administered. Requests for on-going services may depend on completion of previously authorized services in situations where a patient's response to authorized services is relevant to a determination of clinical appropriateness.

# Imaging of the Chest

## General Information/Overview

### Scope

These guidelines address advanced imaging of the chest in both adult and pediatric populations. For interpretation of the Guidelines, and where not otherwise noted, “adult” refers to persons age 19 and older, and “pediatric” refers to persons age 18 and younger. Where separate indications exist, they are specified as **Adult** or **Pediatric**. Where not specified, indications and prerequisite information apply to persons of all ages.

See the Coding section for a list of modalities included in these guidelines.

### Technology Considerations

Anatomic coverage for thoracic imaging includes the area between the lung apices and the costophrenic sulci—specifically, the lung parenchyma, pleura, mediastinum, and musculoskeletal structures of the thorax. Chest imaging studies are not appropriate for cardiac and coronary artery imaging. For imaging of the heart, see the Cerebral guidelines for the specific CPT code being requested. Vascular imaging of the thorax is addressed in the Vascular Imaging guidelines.

In the majority of clinical situations, chest radiographs should have been performed within 30 days of the imaging request. When radiographs are not sufficient to guide management, **computed tomography (CT)** is most often the study of choice for imaging the thorax; it is widely available and provides excellent resolution of soft tissue and the bony thorax.<sup>1</sup> **High-resolution CT (HRCT)** uses thin-section acquisition and high spatial frequency reconstruction to optimize visualization of the fine lung parenchyma and airways.<sup>2</sup> It is primarily indicated for characterization of diffuse lung or small airways disease. HRCT is usually performed without contrast and using dynamic (inspiratory and expiratory) breathing, and often produces a lower radiation dose than a standard chest CT.<sup>3</sup> **Low-dose chest CT (LDCT)** also employs a dose reduction strategy and is primarily used in lung cancer screening.<sup>4, 5</sup> Disadvantages of CT include exposure to ionizing radiation and risks associated with infusion of iodinated contrast media, including allergic reactions or renal compromise.

**Magnetic resonance imaging (MRI)** is generally less useful for thoracic imaging; speed of image acquisition is slower and motion artifact in this region may interfere with image quality. However, it does provide superior resolution of the lung apices and chest wall (including breast). It may also be used for problem solving following CT, or for situations in which CT is contraindicated. **Breast MRI** requires a dedicated breast coil. For breast imaging related to cancer screening or diagnosis, see Oncologic Imaging guidelines. The presence of implantable devices such as pacemakers or defibrillators, a potential need for sedation in pediatric patients, and claustrophobia are the main limitations of MRI. Infusion of gadolinium may also confer an unacceptable risk in persons with advanced renal disease.

### Definitions

Phases of the care continuum are broadly defined as follows:

- **Screening** – testing in the absence of signs or symptoms of disease
- **Diagnosis** – testing based on a reasonable suspicion of a particular condition or disorder, usually due to the presence of signs or symptoms
- **Management** – testing to direct therapy of an established condition, which may include preoperative or postoperative imaging, or imaging performed to evaluate the response to nonsurgical intervention
- **Surveillance** – periodic assessment following completion of therapy, or for monitoring known disease that is stable or asymptomatic

## Statistical terminology

- **Confidence interval (CI)** – range of values which is likely to contain the cited statistic. For example, 92% sensitivity (95% CI, 89%-95%) means that, while the sensitivity was calculated at 92% on the current study, there is a 95% chance that, if a study were to be repeated, the sensitivity on the repeat study would be in the range of 89%-95%.
- **Diagnostic accuracy** – ability of a test to discriminate between the target condition and health. Diagnostic accuracy is quantified using sensitivity and specificity, predictive values, and likelihood ratios.
- **Hazard ratio** – odds that an individual in the group with the higher hazard reaches the outcome first. Hazard ratio is analogous to odds ratio and is reported most commonly in time-to-event analysis or survival analysis. A hazard ratio of 1 means that the hazard rates of the 2 groups are equivalent. A hazard ratio of greater than 1 or less than 1 means that there are differences in the hazard rates between the 2 groups.
- **Likelihood ratio** – ratio of an expected test result (positive or negative) in patients *with* the disease to an expected test result (positive or negative) in patients *without* the disease. Positive likelihood ratios, especially those greater than 10, help rule in a disease (i.e., they substantially raise the post-test probability of the disease, and hence make it very likely and the test very useful in identifying the disease). Negative likelihood ratios, especially those less than 0.1, help rule out a disease (i.e., they substantially decrease the post-test probability of disease, and hence make it very unlikely and the test very useful in excluding the disease).
- **Odds ratio** – odds that an outcome will occur given a particular exposure, compared to the odds of the outcome occurring in the absence of that exposure. An odds ratio of 1 means that the exposure does not affect the odds of the outcome. An odds ratio greater than 1 means that the exposure is associated with higher odds of the outcome. An odds ratio less than 1 means that the exposure is associated with lower odds of the outcome.
- **Predictive value** – likelihood that a given test result correlates with the presence or absence of disease. Positive predictive value is defined as the number of true positives divided by the number of test positives. Negative predictive value is defined as the number of true negatives divided by the number of test negative patients. Predictive value is dependent on the prevalence of the condition.
- **Pretest probability** – probability that a given patient has a disease prior to testing. May be divided into very low (less than 5%), low (less than 20%), moderate (20%-75%), and high (greater than 75%) although these numbers may vary by condition.
- **Relative risk** – probability of an outcome when an exposure is present relative to the probability of the outcome occurring when the exposure is absent. Relative risk is analogous to odds ratio; however, relative risk is calculated by using percentages instead of odds. A relative risk of 1 means that there is no difference in risk between the 2 groups. A relative risk of greater than 1 means that the outcome is more likely to happen in the exposed group compared to the control group. A relative risk less than 1 means that the outcome is less likely to happen in the exposed group compared to the control group.
- **Sensitivity** – conditional probability that the test is positive, given that the patient has the disease. Defined as the true positive rate (number of true positives divided by the number of patients with disease). Excellent or high sensitivity is usually greater than 90%.
- **Specificity** – conditional probability that the test is negative, given that the patient does not have the disease. Defined as the true negative rate (number of true negatives divided by the number of patients without the disease). Excellent or high specificity is usually greater than 90%.



## Clinical Indications

The following section includes indications for which advanced imaging of the chest is considered medically necessary, along with prerequisite information and supporting evidence where available. Indications, diagnoses, or imaging modalities not specifically addressed are considered not medically necessary.

It is recognized that imaging often detects abnormalities unrelated to the condition being evaluated. Such findings must be considered within the context of the clinical situation when determining whether additional imaging is required.

## Congenital and Developmental Conditions

---

### Congenital thoracic anomalies

Advanced imaging is considered medically necessary for diagnosis and management.

#### IMAGING STUDY

- CT chest

### Congenital pulmonary airway malformation (Pediatric only)

Advanced imaging is considered medically necessary for diagnosis and management of **EITHER** of the following conditions:

- Congenital lobar emphysema
- Congenital cystic adenomatoid malformation

#### IMAGING STUDY

- CT chest

### Chest wall deformities including pectus excavatum (Pediatric only)

Advanced imaging is considered medically necessary in **EITHER** of the following scenarios:

- Preoperative evaluation
- Postoperative evaluation for complications or recurrence

#### IMAGING STUDY

- CT or MRI chest

### Pulmonary sequestration

Advanced imaging is considered medically necessary for diagnosis and management.

#### IMAGING STUDY

- CT chest

## Infectious and Inflammatory Conditions

---

### Pneumonia

Advanced imaging is considered medically necessary in **ANY** of the following scenarios:

- Radiographs show no improvement following at least 4 weeks of medical treatment

- Recurrence of pneumonia in the same location within 6 months
- Evaluation of known or suspected complications of pneumonia following nondiagnostic radiographs
- Immunosuppressed patients with signs or symptoms of pneumonia

### IMAGING STUDY

- CT chest

### Rationale

#### PERSISTENT ABNORMAL RADIOGRAPHS

Clinical signs and symptoms of pneumonia resolve faster than findings on radiography, but may take up to 3 months to resolve.<sup>7,8</sup> It is common for pneumonia to persist on radiographs after clinical resolution, with the rate of radiographic clearance estimates at 35% within 3 weeks and 84% within 12 weeks.<sup>9,10</sup> Patients over age 50 are 2 to 4 times more likely to have delayed radiographic resolution of pneumonia. Therefore, it is important to wait at least 4 weeks after clinical resolution before performing advanced imaging, to exclude non-infectious causes of persistent airspace disease.

#### RECURRENT PNEUMONIA

Recurrent pneumonia is defined as at least 2 episodes of pneumonia in 1 year or 3 lifetime episodes. Evidence is insufficient to inform the optimal timing of imaging in recurrent pneumonia. Bronchoscopy can effectively evaluate the most common causes of recurrent focal airspace disease, including foreign bodies, mucous plugging, and other intraluminal obstructions. However, practice consensus is that CT may be indicated when bronchoscopy is inconclusive. Recurrent pneumonia in the same area is likely due to underlying structural disease—primarily right middle lobe syndrome (airway disease of uncertain pathophysiology) (61%) and congenital lung malformations (21%); diagnostic imaging involving bronchoscopy with or without CT is indicated.<sup>6,11</sup> Recurrent pneumonia in different areas is more likely due to systemic illness (60% related to cystic fibrosis, primary ciliary dyskinesia, or severe gastroesophageal reflux disease) and a more extensive clinical/lab workup is usually performed prior to diagnostic imaging, which is reserved for situations where lab testing (such as immune status assessment, sweat chloride test for cystic fibrosis, tuberculin skin test, pulmonary function tests, and echocardiogram) is inconclusive.<sup>6,11</sup>

### Other infectious or inflammatory conditions

Advanced imaging is considered medically necessary for diagnosis and management of **ANY** of the following conditions:

- Lung abscess
- Sternal wound infection or dehiscence
- Mediastinitis
- Infectious and inflammatory conditions not listed elsewhere in this guideline

### IMAGING STUDY

- CT chest

## Trauma

---

### Blunt or penetrating trauma to the thorax

*Also see Vascular Imaging guidelines.*

Advanced imaging is considered medically necessary for diagnosis and management.

### IMAGING STUDY

- CT chest

## Tumor or Neoplasm

---

The following section addresses conditions which may be indicative of underlying neoplasm, as well as benign tumors of the thorax. For cancer screening guidelines and management of documented malignancy, please refer to the Oncologic Imaging guidelines.

### Chest wall mass

Advanced imaging is considered medically necessary in **ANY** of the following scenarios:

- Palpable chest wall mass with nondiagnostic radiograph or ultrasound
- Chest wall mass identified on prior imaging when further information is needed to determine need for biopsy or surgery
- Preoperative planning following biopsy

*Note: For breast masses (including gynecomastia), see Oncologic Imaging guidelines for breast cancer.*

### IMAGING STUDY

- CT or MRI chest

### Pulmonary nodule or mass

*For biopsy planning, see Perioperative or periprocedural evaluation, not otherwise specified.*

Advanced imaging is considered medically necessary in the following scenarios:

#### Pulmonary nodules detected on lung cancer screening CT

- Follow up according to the most current version of Lung-RADS

#### Calcified nodules detected on a diagnostic chest CT

- Follow up of calcified nodules other than those with benign calcification patterns\* is at the discretion of the ordering provider

*\*Benign calcification patterns include granulomas and popcorn calcifications, for which routine follow up is not medically necessary*

#### Noncalcified nodules detected on a diagnostic chest CT

- Younger than age 35
  - Nodules  $\geq$  1 cm or with suspicious morphology (includes nodules with irregular or spiculated margins)
- Age 35 or older
  - Solid nodules: see **Table 1**
  - Subsolid nodules: see **Table 2**

*\* Carelon Guidelines for pulmonary nodules follow the 2017 recommendations of the Fleischner Society, a high-quality evidence-based guideline directly applicable to American patients.<sup>12</sup> These recommendations apply to patients age 35 or older who are not immunocompromised, who do not have cancer, and who are not enrolled in a lung cancer screening program.*

#### Nodules identified on incomplete thoracic CT

- Less than 6 mm: see table 1 or 2 “less than 6 mm”
- 6 mm to 8 mm: 3 to 12 month follow up with complete chest CT; subsequent follow up based on characterization of nodule

- Greater than 8 mm or suspicious morphology\*: complete chest CT with subsequent follow up based on characterization of nodule

\*Suspicious morphology includes nodules with irregular or spiculated margins

### IMAGING STUDY

- CT chest (all indications)
- FDG-PET, FDG-PET/CT when **BOTH** of the following are criteria are met:
  - Nodule is well-demarcated, solid or part solid, and lacks a benign calcification pattern.
  - Size is greater than 8 mm in greatest diameter

Table 1. Follow-up recommendations for solid noncalcified pulmonary nodules

Solid nodule size	Risk	Solitary	Multiple
Less than 6 mm	Low	No follow up	No follow up
Less than 6 mm	<b>High*</b>	Optional follow-up exam at 12 months	Optional follow-up exam at 12 months
6 mm to 8 mm	N/A	1. 6 to 12 months 2. 18 to 24 months	1. 3 to 6 months 2. 18 to 24 months
More than 8 mm	N/A	1. 3 months 2. 6 months 3. 18 to 24 months unless FDG-PET/CT or tissue sampling performed and provided a definitive diagnosis	1. 3 to 6 months 2. 18 to 24 months
Any size when prior imaging has documented 24 months of stability	N/A	No follow up	No follow up

\*High risk includes the following:

- Smoking history (any)
- First-degree relative with lung cancer
- Significant exposure to asbestos, uranium and/or radon, typically through high-risk profession

Table 2. Follow-up recommendations for subsolid noncalcified pulmonary nodules

Subsolid nodule size	Solitary ground glass	Solitary part solid	Multiple subsolid
Less than 6 mm	No routine follow up	No routine follow up	1. 3 to 6 months 2. 24 months 3. 48 months
Greater than or equal to 6 mm	1. 6 to 12 months 2. Every 2 years thereafter for a total of 5 years	1. 3 to 6 months 2. Every year for 5 years	1. 3 to 6 months 2. Follow up based on most suspicious nodule (part solid or ground glass)

Abbreviation: Lung-RADS™, American College of Radiology Lung CT Screening Reporting and Data System. Adapted from MacMahon H, Naidich DP, Goo JM, et al. *Radiology*. 2017; 284(1):228-243.<sup>12</sup>

## Rationale

Carelon Guidelines for pulmonary nodules follow the 2017 recommendations of the Fleischner Society, a high-quality evidence-based guideline directly applicable to American patients.<sup>12</sup> These recommendations apply to asymptomatic patients age 35 or older who are not immunocompromised, who do not have cancer, and who are not enrolled in a lung cancer screening program.

Fleischner endorses the use of Lung-RADS guidelines to determine follow up when pulmonary nodules are detected as part of a lung cancer screening program. Carelon Guidelines incorporate the use of Lung-RADS for follow up of pulmonary nodules detected on lung cancer screening CT.

### SOLID PULMONARY NODULE IN ASYMPTOMATIC PATIENTS UNDER AGE 35

Primary lung cancer is rare in persons under age 35 (1% of all cases), and the risks from radiation exposure are greater. In young patients, infectious/inflammatory causes are more likely than cancer, and use of serial CT should be minimized. Exceptions may include nodules greater than 1 cm in size or with suspicious morphology. In such cases, follow-up imaging is at the ordering provider's discretion; a single 12-month follow-up CT may be considered to confirm stability.

Most nodules smaller than 1 cm will not be visible on chest radiographs; however, for larger solid nodules that are clearly visualized and are considered low risk, follow up with radiography rather than CT may be appropriate for lower radiation exposure.

### NODULE SMALLER THAN 6 mm SEEN ON PREVIOUS IMAGING

Nodules of this size do not require routine follow up in low-risk patients. Since the average risk of cancer in solid nodules smaller than 6 mm in high-risk patients is less than 1%, and the relative risk of cancer in a nonsmoker is much less (0.15) than in a smoker, the risk of malignancy in low-risk patients is very low.

For high-risk patients, some nodules of this size with suspicious morphology, upper lobe location, or both may warrant follow up at 12 months. These features may increase cancer risk to 1%-5%.

### NODULE LARGER THAN 8 mm

High-risk patients should usually proceed directly to FDG-PET/CT or biopsy. CT surveillance is recommended for nodules greater than 8 mm when:

- Nodules have a low (less than 5%) risk of malignancy (as a rule of thumb, patients older than age 70, patients 50-70 years of age with no high-risk features, and patients younger than age 50 with only one high-risk feature)
- Nodules with intermediate risk (5%-65%) especially when FDG-PET/CT is negative or equivocal, and the lesion is too small to biopsy
- Patients are at high surgical risk

## Lymphadenopathy

See *Oncologic Imaging for patients with documented malignancy*. Thoracic lymphadenopathy is defined as at least one lymph node greater than 1 cm in short axis diameter.

Advanced imaging is considered medically necessary for diagnosis, management, or surveillance in **ANY** of the following scenarios:

- Palpable thoracic or supraclavicular lymph nodes, when not amenable to percutaneous biopsy
- Mediastinal or hilar lymph nodes when **ANY** of the following is present:
  - Suspected by non-advanced imaging (i.e. chest radiography)
  - Single follow up at least 3 months after discovery of nodes with a short axis diameter greater than 1.4 cm without suspicious features
  - Associated clinical or lab findings suggestive of malignancy, especially lymphoma or testicular carcinoma
  - Lymphadenopathy with suspicious features:
    - Necrosis
    - Loss of fatty hilar morphology

- Heterogenous or hypervascular enhancement
- Irregular borders
- Interval enlargement
- Multiple enlarged nodes on the same side of the mediastinum (ipsilateral/unilateral)

#### IMAGING STUDY

- CT chest
- FDG-PET/CT in patients with multiple abnormal (by size or feature) lymph nodes when CT is insufficient to determine the optimal node to biopsy

#### Rationale

Enlarged or borderline enlarged mediastinal lymph nodes are not infrequently seen on chest CT examinations performed for other indications. While the pretest probability of nodal malignancy in patients without a known primary is low, lymphoproliferative disease and occult malignancy are important differential considerations. The American College of Radiology (ACR) has published a consensus based white paper on the management of incidental mediastinal lymph nodes to address appropriate use of surveillance imaging for incidental mediastinal lymphadenopathy.<sup>13</sup> If there is no satisfactory clinical explanation for the nodes, they recommend 3-6 month follow up (commonly done with chest CT) for lymph nodes greater than 14 mm in short axis diameter. Nodes that are stable or that decreased during the interval do not require further follow up. Enlarging nodes may require biopsy and FDG-PET/CT can be used to direct biopsy when multiple options exist. More intensive management including biopsy, FDG-PET/CT, or follow up may be beneficial in patients with additional signs and symptoms of malignancy or in lymph nodes with features that confer a higher post test likelihood of malignant disease. Enlarged palpable lymph nodes of the chest wall can usually be assessed with ultrasound and biopsy as needed.

#### Other thoracic mass lesions

Advanced imaging is considered medically necessary for diagnosis and management of **ANY** of the following findings or conditions:

- Mediastinal mass (see separate indication for lymphadenopathy)
- Pancoast tumor
- Pleural mass
- Thymoma
- Benign tumors (pediatric only)

#### IMAGING STUDY

##### ADULT

- CT chest
- MRI chest for evaluation of mediastinal and hilar masses when CT is insufficient for problem solving or for evaluation of chest wall extension in Pancoast tumor

##### PEDIATRIC

- CT or MRI chest

### Parenchymal Lung Disease – not otherwise specified

---

#### Bronchiectasis

Advanced imaging is considered medically necessary for diagnosis and management.

#### IMAGING STUDY

- CT chest
- Consider chest HRCT technique

## Bronchiolitis obliterans

Advanced imaging is considered medically necessary for diagnosis and management.

### IMAGING STUDY

- CT chest

## Interstitial lung disease (ILD), non-occupational including idiopathic pulmonary fibrosis (IPF)

*In a patient with persistent cough but without other signs or symptoms, please see the Chronic cough indication.*

Advanced imaging is considered medically necessary in **ANY** of the following scenarios:

Diagnosis when **ANY** of the following are present:

- Persistent breathlessness on exertion
- Bilateral inspiratory crackles on physical exam
- Clubbing of the fingers
- Suggestive of ILD/IPF on other diagnostic tests (chest radiography, pulmonary function)
- Additional risk factors (**ANY** of the following):
  - Connective tissue disease
  - Predisposing drugs
  - Known telomerase mutation
  - Familial ILD/IPF with at least two affected first-degree relatives

Management when **ANY** of the following are present:

- Worsening pulmonary signs or symptoms
- Progression of disease on other diagnostic tests (chest radiography, pulmonary function)
- To direct biopsy when initial imaging does not show a pattern consistent with definite usual interstitial pneumonitis (UIP)

### IMAGING STUDY

- CT chest (high resolution (HRCT) technique preferred)

### Rationale

Interstitial lung disease (ILD) is an umbrella term for a variety of diseases that cause fibrosis of the pulmonary interstitium. For patients with suggestive symptoms or lab abnormalities, such as a restrictive pattern on pulmonary function testing, high resolution chest CT is the best noninvasive test to establish the diagnosis and is recommended by both evidence and consensus based guidelines.<sup>14,15,16,17</sup> CT can make a confident diagnosis of usual interstitial pneumonitis (UIP), an irreversible form of pulmonary fibrosis with high morbidity and mortality in many cases avoiding biopsy. CT can also suggest etiologies for the disease. Repeat CT may be indicated in patients with known pulmonary fibrosis and worsening symptoms or to direct biopsy in patients with probable UIP.

## Occupational lung disease (Adult only)

Advanced imaging is considered medically necessary for diagnosis and management of **ANY** of the following conditions:

- Asbestosis
- Berylliosis
- Silicosis
- Coal worker's pneumoconiosis
- Progressive massive fibrosis
- Hard metal pneumoconiosis
- Talcosis
- Caplan's syndrome in patients with rheumatoid arthritis

#### **IMAGING STUDY**

- CT chest

#### **Rationale**

Interstitial lung disease (ILD) can occur from a variety of occupational exposures, the most common being asbestosis and silicosis. CT is more accurate than radiography<sup>18</sup> for the diagnosis and management of asbestosis related lung disease and is recommended by guidelines.<sup>19</sup> Guidelines also recommended CT for the diagnosis and management of silicosis and pneumoconiosis.<sup>19</sup>

### **Pulmonary embolism**

*See Vascular Imaging guidelines.*

### **Sarcoidosis**

Advanced imaging is considered medically necessary for diagnosis and management.

#### **IMAGING STUDY**

- CT chest

## **Pleural Conditions**

---

### **Bronchopleural fistula (Adult only)**

Advanced imaging is considered medically necessary for diagnosis and management.

#### **IMAGING STUDY**

- CT chest

### **Pleural fluid collection**

Advanced imaging is considered medically necessary for diagnosis and management of **ANY** of the following conditions:

- Pleural effusion
- Hemothorax
- Empyema
- Chylothorax

#### **IMAGING STUDY**



- CT chest

*Note: Ultrasound should be considered as the initial imaging modality and prior to a diagnostic or therapeutic pleural tap.*

## **Pneumothorax, unexplained or recurrent**

Advanced imaging is considered medically necessary for diagnosis and management.

### **IMAGING STUDY**

- CT chest

## **Chest Wall and Diaphragmatic Conditions**

---

### **Breast implant rupture**

*See breast cancer section of the Oncologic Imaging guidelines for suspected breast implant associated anaplastic large cell lymphoma (BIA-ALCL)*

Advanced imaging is considered medically necessary in the following scenario:

- Detection of rupture in symptomatic patients with silicone breast implants

### **IMAGING STUDY**

- MRI breast

### **Rationale**

MRI is considered the gold standard in the evaluation of patients with suspected rupture of silicone implants and is recommended for the evaluation of symptomatic patients.<sup>20</sup> MRI has significantly greater diagnostic accuracy compared to ultrasound and is especially sensitive for the diagnosis of intracapsular rupture.<sup>21,22,23</sup> MRI is not recommended by evidence based guidelines for the evaluation of asymptomatic breast implants due to lower diagnostic accuracy and higher risk of false positives with unclear impact on patient management.<sup>20</sup> MRI is also not necessary and is not recommended for the evaluation of saline breast implants.<sup>20</sup>

### **Diaphragmatic hernia**

Advanced imaging is considered medically necessary for diagnosis and management.

### **IMAGING STUDY**

- CT chest

### **Pectoralis muscle tear**

Advanced imaging is considered medically necessary for preoperative planning in patients with suspected full thickness tear of the tendon or myotendinous junction.

### **IMAGING STUDY**

- MRI chest

### **Thoracic outlet syndrome**

*Also see Vascular Imaging guidelines.*

Advanced imaging is considered medically necessary for diagnosis and management.

### **IMAGING STUDY**

- CT or MRI chest for neurogenic thoracic outlet syndrome
- CTA or MRA chest for vascular thoracic outlet syndromes

## Perioperative or periprocedural evaluation, not otherwise specified

---

### Lung volume reduction procedures

Advanced imaging is considered medically necessary for evaluation prior to planned lung volume reduction procedures<sup>24, 25</sup>

#### IMAGING STUDY

- CT chest

### Navigational bronchoscopy planning for pulmonary mass or nodule

Advanced imaging is considered medically necessary for use in navigational bronchoscopy when being done for **EITHER** of the following reasons:

- Planning of a biopsy to be done using navigational bronchoscopy, when neither percutaneous biopsy nor traditional bronchoscopy can be performed.
- Placement of fiducial markers for radiation therapy or localization for surgical resection of a pulmonary mass

#### IMAGING STUDY

- CT chest

### Transplant-related imaging

Advanced imaging is considered medically necessary in the following scenarios:

- Single evaluation prior to lung, liver, kidney, or hematopoietic stem cell transplantation
- Evaluation for complications following lung, liver, kidney, or hematopoietic stem cell transplantation

*Note: For patients on the transplant list but who have not undergone transplantation and who have a change in clinical condition, please refer to the applicable sign- or symptom-based indication.*

#### IMAGING STUDY

- CT chest

## Signs and Symptoms

---

### Cough (chronic or persistent)

Advanced imaging is considered medically necessary for evaluation of cough present for at least 8 weeks in the following scenarios:

- Cough not responding to appropriate treatment and unexplained by clinical evaluation, chest radiography, and pulmonary function testing or spirometry
- Cough in immunosuppressed individuals

*Note: Chronic cough, in the context of other signs and symptoms, should be evaluated based on the most likely disease or diseases responsible (see indication for bronchiectasis or interstitial lung disease).*

## IMAGING STUDY

- CT chest

### Rationale

#### CHRONIC COUGH IN ADULTS

Advanced imaging cannot diagnose the most common causes of chronic cough and the most common causes of cough should first be evaluated prior to advanced imaging.<sup>26,27</sup>

Likely causes of chronic cough without conclusive chest X-ray and lung function include upper airway cough syndrome, cough-variant asthma, gastroesophageal reflux,<sup>26</sup> primary and secondary smoking, environmental and occupational irritants, and ACE inhibitors.<sup>27</sup>

Stepwise workup of chronic cough without conclusive chest X-ray is recommended. Before performing HRCT or bronchoscopy, consider asthma, COPD, upper airway cough syndrome, and gastroesophageal reflux.<sup>26</sup>

#### CHRONIC COUGH IN PEDIATRIC PATIENTS

The majority of pediatric patients with chronic wet cough will respond to antibiotic treatment with a number needed to treat of 3.<sup>28,29</sup>

## Fever of unknown origin

Advanced imaging is considered medically necessary in **EITHER** of the following scenarios:

- Fever of duration greater than 3 weeks, which is unexplained following a standard diagnostic evaluation to identify the source
- Unexplained fever in immunocompromised patient

## IMAGING STUDY

- CT chest

## Hemoptysis

Advanced imaging is considered medically necessary for evaluation following nondiagnostic chest radiographs.

## IMAGING STUDY

- CT chest
- MRI chest for suspected vascular anomaly in pediatric patients

*Note: Bronchoscopy is a complementary modality to assess hemoptysis.*

### Rationale

Hemoptysis is defined as the expectoration of blood that originates from the tracheobronchial tree or pulmonary parenchyma and is usually categorized based on the volume and rate of bleeding with massive hemoptysis defined as 300-400 cc of expectorated blood in a 24-hour period.<sup>30</sup>

The most common causes of hemoptysis are bronchiectasis, tuberculosis, pneumonia, and cancer. Radiographs can identify the cause of hemoptysis between 35% and 50% of the time.<sup>31</sup> Guidelines recommend radiography as the preferred initial imaging modality in patients with non-massive hemoptysis.<sup>32,33</sup> CT is indicated in patients with a negative radiograph and persistent unexplained hemoptysis as it is significantly more sensitive (overall 64%-100%) than any other imaging modality.<sup>31</sup>

Hemoptysis is rare in children and very rarely due to malignant etiologies. The ALARA (as low as reasonably achievable) principle dictates that radiography and bronchoscopy should both be considered prior to CT in children. As in adults, however, CT is more sensitive than both radiography and bronchoscopy and could be considered in pediatric cases where the initial workup is nondiagnostic.<sup>34</sup>

Massive hemoptysis is a rare (less than 5% of cases) medical emergency typically evaluated and treated with bronchoscopy.<sup>31</sup> CT performed before or after a nondiagnostic bronchoscopy is complementary and more sensitive for the diagnosis as it can

visualize the lung parenchyma and mediastinum in addition to the tracheobronchial tree.<sup>33</sup> CT frequently changes management in these patients.<sup>33, 35</sup>

## Hoarseness, dysphonia, and vocal cord weakness/paralysis – primary voice complaint

*Also see Head and Neck Imaging guidelines.*

Advanced imaging is considered medically necessary for initial evaluation in **EITHER** of the following scenarios:

- Following laryngoscopy, when findings suggest recurrent laryngeal nerve dysfunction or identify a suspicious lesion
- Evaluation of symptoms persisting longer than 1 month which are unexplained by laryngoscopy

### IMAGING STUDY

- CT chest

### Rationale

Most hoarseness is self-limited or caused by a pathology that can be identified by laryngoscopy.

Clinicians should visualize the patient's larynx, or refer the patient to a clinician who can visualize the larynx, when hoarseness fails to resolve by a maximum of 3 months after onset, or irrespective of duration if a serious underlying cause is suspected.<sup>36, 37</sup>

Benign lesions of the vocal cords such as cysts, nodules, polyps, and gastroesophageal reflux are frequently diagnosed and managed with laryngoscopy alone. Accuracy of history and physical exam in hoarseness is low (~5%), laryngoscopy increases the accuracy of diagnosis by ~68%.<sup>38</sup>

Hoarseness is common in young children (15%-24%) and usually due to benign lesions seen on laryngoscopy such as vocal cord nodules, which account for approximately 77% of cases.<sup>36</sup>

The American Academy of Otolaryngology-Head and Neck Surgery recommends not obtaining CT or MRI in patients with a primary complaint of hoarseness prior to examining the larynx.<sup>39</sup>

## Horner's syndrome

*Also see Brain Imaging and Head and Neck Imaging guidelines.*

Advanced imaging is considered medically necessary for diagnosis and management.

### IMAGING STUDY

- CT or MRI chest

## Paraneoplastic syndrome

*Also see Oncologic Imaging guidelines.*

Advanced imaging is considered medically necessary for diagnosis and management.

### IMAGING STUDY

- CT chest

### Rationale

Paraneoplastic syndromes occur when a tumor secretes bioactive substances that result in signs and/or symptoms distant from its site of origin and unrelated to organ invasion.<sup>40</sup> They occur in about 8% of all cancers and are caused by a variety of neoplasms, especially neuroendocrine tumors like small cell lung cancer. Examples of paraneoplastic syndromes include, but are not limited to, hypercalcemia, syndrome of inappropriate diuretic hormone secretion (SIADH), opsoclonus-myooclonus, stiff person (anti-GAD antibodies), myasthenia gravis (Lambert-Eaton), and encephalitis (NMDA receptor antibody).<sup>40</sup>

Advanced imaging (CT or FDG-PET/CT) is used to identify the primary neoplasm in patients who present with paraneoplastic syndromes of unknown etiology. Chest CT has been shown to have a sensitivity of 89% and a specificity of 93% for the detection of the most common primary associated with paraneoplastic syndrome: lung cancer.<sup>40</sup>

A 2016 systematic review and meta-analysis of 21 studies and 1293 patients examined the comparative diagnostic accuracy of whole body PET or PET-CT in patients presenting with paraneoplastic syndrome. Pooled sensitivity, specificity, and diagnostic odds ratio of <sup>18</sup>F-FDG PET or <sup>18</sup>F-FDG PET/CT for the detection of underlying malignancy were 0.81 (95% CI, 0.76–0.86), 0.88 (95% CI, 0.86–0.90), and 34.03 (95% CI, 18.76–61.72), respectively. The pooled global diagnostic accuracy (area under the curve) was 0.916 (SE, 0.018). Five studies examined the performance of conventional screening modalities for paraneoplastic syndrome including CT and found variable sensitivity ranging from 30%–82% and 71%–100%. The authors comment that there is yet “no consensus on the value of whole-body <sup>18</sup>F-FDG PET or <sup>18</sup>F-FDG PET/CT in patients suspected of harboring a paraneoplastic syndrome... Further studies are needed to investigate the additional value of <sup>18</sup>F-FDG PET/CT and its cost effectiveness over conventional screening modalities.” However, they conclude that “<sup>18</sup>F-FDG PET and <sup>18</sup>F-FDG PET/CT have excellent diagnostic accuracy and moderate to high sensitivity and specificity for the detection of underlying malignancy in patients suspected of having a paraneoplastic syndrome. The systematic review is significantly limited by unexplained heterogeneity in the data, publication, and selection bias along with differential verification using an inconsistent reference standard.”<sup>41</sup>

## Weight loss

*Also see Abdomen and Pelvis Imaging guidelines.*

Advanced imaging is considered medically necessary for evaluation of unintentional weight loss exceeding 5% of body weight within a 12-month interval in **EITHER** of the following scenarios:

- Persistence following a negative comprehensive clinical evaluation (including a history and physical examination, age-appropriate cancer screening, chest radiography, and initial laboratory evaluation) after a period of observation
- Abnormal findings suggestive of malignancy on history, physical exam, imaging, or laboratory evaluation

## IMAGING STUDY

- CT chest

## Rationale

Persistent unintentional weight loss is defined as a substantive weight loss over a period of 6–12 months.<sup>42</sup> Weight loss is not uncommon in elderly patients and is typically related to one of the 7 Ds: dementia, dentition, depression, diarrhea, drugs, functional dysfunction, or dysphagia. When unintentional weight loss remains unexplained, it may be due to the 8<sup>th</sup> D: acute or chronic disease.<sup>42</sup>

The primary purpose of advanced imaging in the evaluation of unexplained unintentional weight loss is to exclude an occult malignancy not detected by initial clinical evaluation and testing, usually in patients with abnormalities on baseline testing. Screening with CT is of limited value. Instead, diagnostic testing should be directed toward areas of concern based on the history and physical examination.<sup>43</sup> Age appropriate screening for malignancy (mammogram, pap smear) should also be encouraged.<sup>44</sup>

The most common cause of malignancy in patients with unintentional weight loss is gastrointestinal primary (47%), and gastrointestinal causes account for 45% of nonmalignant organic etiologies.<sup>45</sup> Therefore, endoscopy and/or colonoscopy should be considered for initial evaluation when there is evidence of a GI source.

CT with contrast is sensitive for the detection of lymphoma, lung, and genitourinary cancers, which are the next most common causes of malignancy in patients with unintentional weight loss.

## Abnormal Test Findings

---

### Imaging abnormalities

Advanced imaging is considered medically necessary for follow up of **ANY** of the following abnormalities identified on chest X-ray or other thoracic imaging study:

- Pulmonary mass, structural or parenchymal abnormality
- Hilar enlargement or mediastinal widening
- Hyperlucent lung in pediatric patients
- Unexplained diaphragmatic elevation or immobility
- Findings on other imaging suggesting tracheal or bronchial pathology

#### IMAGING STUDY

- CT chest

### Positive sputum cytology

Advanced imaging is considered medically necessary for follow up.

#### IMAGING STUDY

- CT chest

### Tracheal or bronchial lesion or other findings on bronchoscopy

Advanced imaging is considered medically necessary for follow up.

#### IMAGING STUDY

- CT chest

## References

1. American College of Radiology. ACR-STR practice parameter for the performance of high-resolution computed tomography (HRCT) of the lungs in adults. 2015.
2. Heitkamp DE, Mohammed TL, Kirsch J, et al. ACR Appropriateness Criteria acute respiratory illness in immunocompromised patients. *J Am Coll Radiol*. 2012;9(3):164-9.
3. Gorycki T, Lasek I, Kaminski K, et al. Evaluation of radiation doses delivered in different chest CT protocols. *Pol J Radiol*. 2014;79:1-5.
4. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. *Thorax*. 2011;66 Suppl 2:ii1-23.
5. Rampinelli C, Origgi D, Bellomi M. Low-dose CT: technique, reading methods and image interpretation. *Cancer Imaging*. 2013;12:548-56.
6. Jones BP, Tay ET, Elikashvili I, et al. Feasibility and safety of substituting lung ultrasonography for chest radiography when diagnosing pneumonia in children: a randomized controlled trial. *Chest*. 2016;150(1):131-8.
7. Imberger G, McIlroy D, Pace NL, et al. Positive end-expiratory pressure (PEEP) during anaesthesia for the prevention of mortality and postoperative pulmonary complications. *Cochrane Database of Systematic Reviews*. 2010(9):CD007922.
8. National Institute for Health and Care Excellence, Pneumonia in adults: diagnosis and management (2014) United Kingdom, The National Institute for Health and Care Excellence.
9. Llamas-Alvarez AM, Tenza-Lozano EM, Latour-Perez J. Accuracy of lung ultrasonography in the diagnosis of pneumonia in adults: systematic review and meta-analysis. *Chest*. 2017;151(2):374-82.
10. El Solh AA, Aquilina AT, Gunen H, et al. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. *J Am Geriatr Soc*. 2004;52(2):224-9.
11. Montella S, Corcione A, Santamaria F. Recurrent pneumonia in children: a reasoned diagnostic approach and a single centre experience. *Int J Mol Sci*. 2017;18(2).
12. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. *Radiology*. 2017;284(1):228-43.
13. Munden RF, Carter BW, Chiles C, et al. Managing incidental findings on thoracic CT: mediastinal and cardiovascular findings. A white paper of the ACR Incidental Findings Committee. *J Am Coll Radiol*. 2018;15(8):1087-96.

14. National Clinical Guideline Centre, Diagnosis and management of suspected idiopathic pulmonary fibrosis, (2013) London, UK, National Institute for Health and Care Excellence, 307 pgs.
15. Johansson KA, Kolb M, Fell CD, et al. Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*. 2017;1(3):133-41.
16. Robalo Cordeiro C, Campos P, Carvalho L, et al. Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis: Joint Consensus of Sociedade Portuguesa de Pneumologia, Sociedade Portuguesa de Radiologia e Medicina Nuclear e Sociedade Portuguesa de Anatomia Patológica. *Revista Portuguesa de Pneumologia (English Edition)*. 2016;22(2):112-22.
17. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med*. 2018;6(2):138-53.
18. Terra-Filho M, Bagatin E, Nery LE, et al. Screening of miners and millers at decreasing levels of asbestos exposure: comparison of chest radiography and thin-section computed tomography. *PLoS One*. 2015;10(3):e0118585.
19. Bacchus L, Shah RD, Chung JH, et al. ACR Appropriateness Criteria Review ACR Appropriateness Criteria occupational lung diseases. *J Thorac Imaging*. 2016;31(1):W1-3.
20. Lourenco AP, Moy L, Baron P, et al. ACR Appropriateness Criteria breast implant evaluation. *J Am Coll Radiol*. 2018;15(5s):S13-s25.
21. Rietjens M, Villa G, Toesca A, et al. Appropriate use of magnetic resonance imaging and ultrasound to detect early silicone gel breast implant rupture in postmastectomy reconstruction. *Plast Reconstr Surg*. 2014;134(1):13e-20e.
22. Maisel Lotan A, Retchkiman M, Tuchman I, et al. Analysis of 109 consecutive explanted breast implants: correlation between suspected implant rupture and surgical findings. *Aesthetic Plast Surg*. 2016;40(5):739-44.
23. Hold PM, Alam S, Pilbrow WJ, et al. How should we investigate breast implant rupture? *Breast Journal*. 2012;18(3):253-6.
24. Michigan Medicine University of Michigan, Ambulatory adult chronic obstructive pulmonary disease guideline, (2020) Ann Arbor, MI, Michigan Medicine University of Michigan, 29 pgs.
25. National institute for Health and Care Excellence, Chronic obstructive pulmonary disease in over 16s: diagnosis and management, (2018) London (UK), National institute for Health and Care Excellence, 72 pgs.
26. Kardos P, Berck H, Fuchs KH, et al. Guidelines of the German Respiratory Society for diagnosis and treatment of adults suffering from acute or chronic cough. *Pneumologie*. 2010;64(11):701-11.
27. Kahrilas PJ, Altman KW, Chang AB, et al. Chronic cough due to gastroesophageal reflux in adults: CHEST guideline and expert panel report. *Chest*. 2016;150(6):1341-60.
28. Mannelli G, Cecconi L, Gallo O. Laryngeal preneoplastic lesions and cancer: challenging diagnosis. Qualitative literature review and meta-analysis. *Critical Reviews in Oncology-Hematology*. 2016;106:64-90.
29. Chang AB, Oppenheimer JJ, Weinberger M, et al. Children with chronic wet or productive cough –treatment and investigations: a systematic review. *Chest*. 2016;149(1):120-42.
30. Ketai LH, Mohammed TL, Kirsch J, et al. ACR appropriateness criteria hemoptysis. *J Thorac Imaging*. 2014;29(3):W19-22.
31. Larici AR, Franchi P, Occhipinti M, et al. Diagnosis and management of hemoptysis. *Diagn Interv Radiol*. 2014;20(4):299-309.
32. Jeudy J, Khan AR, Mohammed TL, et al. ACR Appropriateness Criteria hemoptysis. *J Thorac Imaging*. 2010;25(3):W67-9.
33. Earwood JS, Thompson TD. Hemoptysis: evaluation and management. *Am Fam Physician*. 2015;91(4):243-9.
34. Bannister M. Paediatric haemoptysis and the otorhinolaryngologist: Systematic review. *Int J Pediatr Otorhinolaryngol*. 2017;92:99-102.
35. Chalumeau-Lemoine L, Khalil A, Prigent H, et al. Impact of multidetector CT-angiography on the emergency management of severe hemoptysis. *Eur J Radiol*. 2013;82(11):e742-7.
36. Schwartz SR, Cohen SM, Dailey SH, et al. Clinical practice guideline: hoarseness (dysphonia). *Otolaryngol Head Neck Surg*. 2009;141(3 Suppl 2):S1-s31.
37. Storck C, Buitrago-Tellez C. Multidetector computed tomography in nonmalignant laryngeal disease. *Curr Opin Otolaryngol Head Neck Surg*. 2012;20(6):443-9.
38. Paul BC, Chen S, Sridharan S, et al. Diagnostic accuracy of history, laryngoscopy, and stroboscopy. *Laryngoscope*. 2013;123(1):215-9.
39. Robertson PJ, Brereton JM, Roberson DW, et al. Choosing wisely: our list. *Otolaryngology - Head & Neck Surgery*. 2013;148(4):534-6.
40. Dimitriadis GK, Angelousi A, Weickert MO, et al. Paraneoplastic endocrine syndromes. *Endocr Relat Cancer*. 2017;24(6):R173-r90.
41. Sheikhbahaei S, Marcus CV, Fragomeni RS, et al. Whole-body (18)F-FDG PET and (18)F-FDG PET/CT in patients with suspected paraneoplastic syndrome: a systematic review and meta-analysis of diagnostic accuracy. *J Nucl Med*. 2017;58(7):1031-6.
42. Gaddey HL, Holder K. Unintentional weight loss in older adults. *Am Fam Physician*. 2014;89(9):718-22.
43. Stajkovic S, Aitken EM, Holroyd-Leduc J. Unintentional weight loss in older adults. *CMAJ*. 2011;183(4):443-9.



44. Wong CJ. Involuntary weight loss. *Med Clin North Am.* 2014;98(3):625-43.
45. Bosch X, Monclus E, Escoda O, et al. Unintentional weight loss: clinical characteristics and outcomes in a prospective cohort of 2677 patients. *PLoS One.* 2017;12(4):e0175125.

## Codes

The following code list is not meant to be all-inclusive. Authorization requirements will vary by health plan. Please consult the applicable health plan for guidance on specific procedure codes.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

### CPT/HCPCS

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

71250	Computed tomography, thorax, diagnostic; without contrast material
71260	Computed tomography, thorax, diagnostic; with contrast material(s)
71270	Computed tomography, thorax, diagnostic; without contrast material, followed by contrast material(s) and further sections
71550	MRI chest, without contrast
71551	MRI chest, with contrast
71552	MRI chest, without contrast, followed by re-imaging with contrast
77046	MRI breast without contrast material(s); unilateral
77047	MRI breast without contrast material(s); bilateral
77048	MRI breast without and with contrast with CAD; unilateral
77049	MRI breast without and with contrast with CAD; bilateral
78811	PET imaging, limited area
78812	PET imaging, skull to mid-thigh
78813	PET imaging, whole body
78814	PET imaging, with concurrently acquired CT for attenuation correction and anatomic localization; limited area
78815	PET imaging, with concurrently acquired CT for attenuation correction and anatomic localization; skull base to mid-thigh
78816	PET imaging, with concurrently acquired CT for attenuation correction and anatomic localization; whole body
C8903	MRI with contrast, breast; unilateral
C8905	MRI without contrast followed by with contrast, breast; unilateral
C8906	MRI with contrast, breast; bilateral
C8908	MRI without contrast followed by with contrast, breast; bilateral

### ICD-10 Diagnosis

Refer to the ICD-10 CM manual

## History

Status	Review Date	Effective Date	Action
Revised	07/18/2023	04/14/2024* *Not for LA Medicaid	Independent Multispecialty Physician Panel (IMPP) review. Added new indication: Navigational bronchoscopy planning for pulmonary mass or nodule.



Status	Review Date	Effective Date	Action
			Added required language to General Clinical Guideline per new Medicare regulations.
Revised	05/09/2022	04/09/2023 for commercial, Medicare, and Medicaid except LA; 06/18/2023 for LA Medicaid	IMPP review. Revised indications: Imaging abnormalities.
Revised	05/09/2022	11/06/2022 for commercial, Medicare, and non-Anthem Medicaid; 04/09/2023 for Anthem Medicaid except LA Medicaid	IMPP review. Added Lung volume reduction procedures indication.
Revised	05/26/2021	03/13/2022	IMPP review. Revised indications Pneumonia, Pulmonary nodule, Interstitial lung disease.
Revised	05/26/2021	11/07/2021	IMPP review. Added Transplant-related imaging indication.
Revised	02/03/2020	03/14/2021	IMPP review. Revised indications include Hoarseness/dysphonia/vocal cord weakness. Added HCPCS codes C8903, C8905, C8906, and C8908.
Revised	-	01/01/2021	Annual CPT code update: revised descriptions for 71250, 71260, 71270.
Revised	03/11/2020	03/12/2020	IMPP review. Revised Pneumonia indication to allow CT for diagnosis of COVID-19 pneumonia.
Revised	10/28/2019	08/17/2020	IMPP review. Updates made to the following indications: Pulmonary nodule, Other thoracic mass lesions, Interstitial lung disease and pulmonary fibrosis, Occupational lung disease, and Breast implant rupture. Added indication for Lymphadenopathy. Moved indication for Asbestos-related lesions.
Restructured	09/12/2018	01/01/2019	IMPP review. Advanced Imaging guidelines redesigned and reorganized to a condition-based structure. Incorporated AIM guidelines for pediatric imaging.
Revised	07/11/2018	03/09/2019	IMPP review. Renamed the Administrative Guidelines to "General Clinical Guideline." Retitled Pretest Requirements to "Clinical Appropriateness Framework" to summarize the components of a decision to pursue diagnostic testing. Revised to expand applicability beyond diagnostic imaging, retitled Ordering of Multiple Studies to "Ordering of Multiple Diagnostic or Therapeutic Interventions" and replaced imaging-specific terms with "diagnostic or therapeutic intervention." Repeated Imaging split into two subsections, "repeat diagnostic testing" and "repeat therapeutic intervention."

Status	Review Date	Effective Date	Action
Reviewed and revised	-	03/12/2018	IMPP review and revision.
Created	-	03/30/2005	Original effective date.